CRIS stock is on the tear in the past few minutes as Curis, Inc. (NASDAQ:CRIS) reports updated data in two abstracts for CA-4948 accepted for presentation at the EHA 2021 Virtual Congress.
Curis announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA). The abstracts include updated data from a February data-cut for its ongoing open-label, single arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).
Updated clinical data from the Phase 1/2 study of CA-4948 in AML and MDS from a February data-cut includes reduction of marrow blasts in 8 out of 9 evaluable patients with elevated blast counts at baseline.
Four objective responses observed, including one complete response (CR), one complete remission with incomplete hematologic recovery (CRi) with negative minimal residual disease, and two bone marrow CRs.
After a brief halt before the news, CRIS stock just resumed trading with a big jump of 59.21% to $15.65 after hitting a new 52-week high of $17.40.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.